Skip to main content
P

Presagen

presagen.com

Website unreachable since Oct 28, 2026

Qubigen combines federated AI technology with virtual screening and AI drug design to create a global proprietary dataset for drug development. This approach enhances the efficiency of drug discovery by enabling secure data collaboration across clinics and research institutions without compromising patient privacy.

Traction 6/10
San Francisco, United States · HQ
Founded 201641K+ followers
  • Artificial Intelligence
  • Data & Analytics
  • Biotechnology
Updated 23 months ago

Funding

Raised to date

$4.3MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

2 founders

Michelle Perugini

CEO UniSA Ventures

undefined undefined

Product

Problem

Traditional drug discovery processes are slow and inefficient, often hampered by limited datasets and the inability to securely collaborate across different research institutions due to patient privacy concerns. This lack of data sharing and collaboration hinders the development of new and effective treatments.

Solution

Qubigen leverages federated AI technology combined with virtual screening and AI drug design to accelerate drug discovery. The company enables secure data collaboration across clinics and research institutions, creating a global proprietary dataset without compromising patient privacy. By using federated learning, Qubigen allows multiple parties to train AI models on their local data without directly exchanging sensitive information. This approach enhances the efficiency of drug discovery by providing a larger, more diverse dataset for training AI models, leading to better predictions and more effective drug candidates.

Target Audience

Qubigen's primary customers are pharmaceutical companies, research institutions, and clinics involved in drug discovery and development.

Features

  • Federated AI technology for secure, privacy-preserving data collaboration
  • Virtual screening capabilities to identify promising drug candidates
  • AI-driven drug design tools to optimize molecular structures
  • Global proprietary dataset for training AI models
This profile is AI-generated and may contain inaccuracies.